stockrowCogent Biosciences, Inc.
COGT Healthcare Biotechnology
- EPS
- +1.89%
- Free cash flow
- −42.0%
Quarter to June 2026, against a year earlier
Follow COGT
Alert me
Cogent Biosciences, Inc. (COGT) Return on assets
Cogent Biosciences, Inc.'s return on assets over the twelve months to 30 June 2026 was −68.0%, down 16.0 percentage points from fiscal 2025 (−52.0%). Over the past ten years it has ranged from −119.3% (fiscal 2020) to −17.6% (fiscal 2015); the current reading is higher than 45% of that period. That is below the Biotechnology industry median of −46.1% and below the Healthcare sector median of −29.5%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −52.0% | 27.80 |
| FY2024 | −79.8% | (17.14) |
| FY2023 | −62.7% | (10.02) |
| FY2022 | −52.6% | (22.70) |
| FY2021 | −29.9% | 89.41 |
| FY2020 | −119.3% | (72.30) |
| FY2019 | −47.0% | 4.13 |
| FY2018 | −51.2% | (10.17) |
| FY2017 | −41.0% | 7.15 |
| FY2016 | −48.2% | (30.59) |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | −3.62% |
| TVTX Travere Therapeutics, Inc. compare | −17.5% |
| CRSP CRISPR Therapeutics AG compare | −19.0% |
| MANE Veradermics Incorporated compare | −20.9% |
| DNTH Dianthus Therapeutics, Inc. compare | −21.8% |
| ERAS Erasca, Inc. compare | −65.3% |
| COGT Cogent Biosciences, Inc. | −68.0% |
| KOD Kodiak Sciences Inc. compare | −94.3% |
| SRRK Scholar Rock Holding Corporation compare | −94.6% |
| Biotechnology industry median | −46.1% |
| Healthcare sector median | −29.5% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on COGT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement